Methyl-α-D-glucopyranosid-2,3-disulfat | 30591-47-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Methyl-α-D-glucopyranosid-2,3-disulfat
• 英文别名: [(2R,3R,4S,5R,6S)-3-hydroxy-2-(hydroxymethyl)-6-methoxy-5-sulfooxyoxan-4-yl] hydrogen sulfate
• CAS: 30591-47-0
• 化学式: C₇H₁₄O₁₂S₂
• 分子量: 354.313
• InChiKey: BIEOSDRFKUIBDD-ZFYZTMLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  203
• 氢给体数：
  4
• 氢受体数：
  12

文献信息

• Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases
  申请人：Waratah Pharmaceuticals, Inc.

  公开号：EP2656839A1

  公开（公告）日：2013-10-30

  The present invention provides a medicament for treating an ocular disease comprising a therapeutically effective amount of a cyclohexanehexol compound of the formula III or IV: wherein X is a cyclohexane ring, wherein R1, R2, R3, R4, R5, and R6 are hydroxyl or at least one of R1, R2, R3, R4, R5, and R6 is independently selected from hydrogen, C1-C6 alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkoxy, C2-C6alkenyloxy, C3-C10cycloalkyl, C4-C10cycloalkenyl, C3-C10cycloalkoxy, C6-C10aryl, C6-C10aryloxy, C6-C10aryl-C1-C3alkoxy, C6-C10aroyl, C6-C10heteroaryl, C3-C10heterocyclic, C1-C6acyl, C1-C6acyloxy, -NH2, -NHR7, -NR7R8, =NR7, -S(O)2R7, -SH, -SO3H, nitro, cyano, halo, haloalkyl, haloalkoxy, hydroxyalkyl, -Si(R7)3, -OSi(R7)3, -CO2H, -CO2R7, oxo, -PO3H, -NHC(O)R7, -C(O)NH2, -C(O)NHR7, -C(O)NR7R8, -NHS(O)2R7, -S(O)2NH2, -S(O)2NHR7, and -S(O)2NR7R8 wherein R7 and R8 are independently selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, C4-C10cycloalkenyl, C6-C10aryl, C6-C10aryl C1-C3alkyl, C6-C10 heteroaryl and C3-C10heterocyclic, and at least one of the remainder of R1, R2, R3, R4, R5, or R6 is hydroxyl; or a pharmaceutically acceptable salt thereof.

  本发明提供了一种 本发明提供了一种治疗眼部疾病的药物，该药物包含治疗有效量的式Ⅲ或Ⅳ的环己基己醇化合物： C3-C10环烷基、C4-C10环烯基、C3-C10环烷氧基、C6-C10芳基、C6-C10芳氧基、C6-C10芳烷基-C1-C3烷氧基、C6-C10芳酰胺基、C6-C10杂芳基、C3-C10杂环基、C1-C6酰基、C1-C6acyloxy、-NH2、-NHR7、-NR7R8、=NR7、-S(O)2R7、-SH、-SO3H、硝基氰基、卤代、卤代烷基、卤代烷氧基、羟基烷基、-Si(R7)3、-OSi(R7)3、-CO2H、-CO2R7、氧代、-PO3H、-NHC(O)R7、-C(O)NH2、-C(O)NHR7、C2-C6烷基、C2-C6炔基、C3-C10环烷基、C4-C10环烯基、C6-C10芳基、C6-C10芳基 C1-C3烷基、C6-C10杂芳基和 C3-C10杂环基，且 R1、R2、R3、R4、R5 或 R6 的其余至少一个是羟基；或其药学上可接受的盐。
• In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases
  申请人：——

  公开号：US20020168753A1

  公开（公告）日：2002-11-14

  Co-incubation of an amyloid protein with sulfated macromolecules as a method for the formation of amyloid plaques. The amyloid protein may be the beta-amyloid protein or the prion protein or the like. Amyoid plaque formation in one embodiment proceeds in vitro and desireably produces amyloid plaques that stain with Congo red and demonstrate a maltese-cross pattern when viewed under polarized light. The method also produces amyloid plaques that demonstrate an “amyloid star” appearance when viewed by transmission electron microscopy. Sulfated macromolecules include a sulfated proteoglycan selected from the group consisting of perlecan, ˜220 kilodalton heparan sulfate proteoglyean, glypican, cerebroglycan, aggrecan, synaptoglycan (SV2PG), syndecan, N-syndecan (also known as syndecan-3), syndecan-1, syndecan-4, neurocan, phosphacan, decorin, biglycan, versican, amphiglycan, lumican, PG-M, PG-M (3), agrin, betaglycan, claustrin, brevican, appican, epican, neuroglycan-C, and fragments thereof. Thw sulfated macromolecule may be a sulfated glycosaminoglycan selected from the group consisting of heparin, heparan sulfate, dermatan sulfate, chondroitin sulfate, keratan sulfate, and fragments thereof. An in vivo assay is also presented for selecting a candidate therapeutic agent for inhibiting or disrupting amyloid plaque deposition or persistence. The assay includes a) pre-forming congophilic maltese-cross amyloid plaques in vitro following incubation of an amyloid protein and a selected sulfated macromolecule, b) using a first cannula and osmotic pump to continuously infuse for a selected duration the pre-formed congophilic maltese-cross amyloid plaques into a tissue or organ, c) changing the first cannulae and osmotic pump with a second cannulae and osmotic pump to administer the candidate therapeutic, and d) detecting the candidate therapeutic's ability to disrupt, reduce, or eliminate congophilic maltese-cross amyloid plaque deposition/persistence in the tissue or organ.

  淀粉样蛋白与硫酸化大分子共孵育是形成淀粉样斑块的一种方法。淀粉样蛋白可以是β-淀粉样蛋白或朊病毒蛋白或类似物。在一个实施方案中，淀粉样斑块的形成是在体外进行的，希望产生的淀粉样斑块能用刚果红染色，并在偏振光下观察时显示出麦芽糖十字图案。该方法还能产生在透射电子显微镜下呈现 "淀粉样星形 "外观的淀粉样斑块。 硫酸化大分子包括硫酸化蛋白聚糖，该蛋白聚糖选自perlecan、˜220 千道尔顿硫酸肝素蛋白聚糖、glypican、cerebroglycan、aggrecan、synaptoglycan (SV2PG)、syndecan、N-syndecan（又称辛迪加-3）、辛迪加-1、辛迪加-4、neurocan、phosphacan、decorin、biglycan、versican、amphiglycan、lumican、PG-M、PG-M (3)、agrin、betaglycan、claustrin、brevican、appican、epcan、neuroglycan-C 及其片段。硫酸化大分子可以是从肝素、硫酸肝素、硫酸真皮素、硫酸软骨素、硫酸角蛋白及其片段组成的组中选出的硫酸化糖胺聚糖。 还介绍了一种体内检测方法，用于选择候选治疗药物，以抑制或破坏淀粉样蛋白斑块的沉积或持续存在。该试验包括 a) 在淀粉样蛋白和选定的硫酸化大分子孵育后，在体外预先形成嗜麦芽糖样交叉淀粉样斑块；b) 使用第一插管和渗透泵，在选定的持续时间内将预先形成的嗜麦芽糖样交叉淀粉样斑块持续注入组织或器官、c) 将第一插管和渗透泵换成第二插管和渗透泵，以施用候选疗法，以及 d) 检测候选疗法破坏、减少或消除组织或器官中嗜麦芽糖样交叉淀粉样斑块沉积/存在的能力。
• COMPOUNDS AND METHODS FOR MODULATING CEREBRAL AMYLOID ANGIOPATHY
  申请人：Neurochem, Inc.

  公开号：EP1251837A2

  公开（公告）日：2002-10-30
• INOSITOL DERIVATIVES AND THEIR USES IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DESPOSITION, ACCUMULATION OR PERSISTENCE
  申请人：Waratah Pharmaceuticals, Inc.

  公开号：EP1940373A2

  公开（公告）日：2008-07-09
• EP1940373A4
  申请人：——

  公开号：EP1940373A4

  公开（公告）日：2009-05-27